Advances in drug development: New approaches to thyroid cancer

摘要

EC Thyroid cancer is not uncommon. Approximately 200,000 individuals within the United States have been diagnosed with thyroid cancer. The incidence is approximately 20,000 diagnoses per year. The sizeable difference between incidence and prevalence reflects the fact that most patients survive. The prognosis is excellent for the most part. For instance, the 5-year survival rate for papillary thyroid cancer is over 90%, and the prognosis for fol-licular thyroid cancer is close to that. There are, however, subtypes that carry a worse prognosis, the most notorious being anaplastic thyroid cancer. Fortunately, this entity makes up only 1-2% of all thyroid cancers.